For immediate release
September 27, 2016

Reapplix confirms new funds raised

Birkerød, Denmark, September 27, 2016 Reapplix today announced that it has successfully closed a new funding round of €2.7 million. This new funding was provided by the existing investors, SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).

The new funding will be used to provide continuing forward momentum to the final stages of pre-revenue value creation through to 2018, when Reapplix intends to raise further growth capital in order to undertake the full commercial launch of its lead product, LeucoPatch®.

Graeme Brookes, Chief Executive Officer at Reapplix, commented on the news: *"Having completed the product development and obtained regulatory clearance in both Europe and USA, we are now awaiting the completion in 2017 of our large scale randomized controlled trial, which will be key to gaining reimbursement. This new funding allows us to continue to invest in clinical evidence and in parallel accelerate our work building commercial proof of principle and extensive user traction in selected markets"*

-ends-

For further information, please contact:

Graeme Brookes, CEO at Reapplix ApS, +45 53777447 or email gnb@reapplix.com

Tony Stephenson, Exitus Communications, +44 7899 796655 or email

tony@exituscommunications.co.uk

- Notes to editors -

Reapplix have developed a unique device technology for tissue regeneration, which is currently being focused on wound care. In Europe, this technology is known as the LeucoPatch® System and is undergoing both clinical evaluation and commercial market testing. In the LeucoPatch® System, blood is collected from the patient in a single use LeucoPatch® Device, which is a precision engineered mini cell processor. The LeucoPatch® Device, in combination with the LeucoPatch 3CP™ Centrifuge, uses the patent protected 3CP™ Technology to produce each autologous LeucoPatch® on

demand using a simple to use process, with no reagents, which fits in well with existing clinical work flow.

LeucoPatch® is currently being used at selected centres across Europe to treat a variety of hard to heal wounds. In addition to this, LeucoPatch® is being evaluated for the treatment of diabetic foot ulcers in a 250 patient randomized controlled clinical study that is expected to be completed in 2017. Diabetic foot ulcers are associated with high morbidity and substantial health care costs as up to 40% of diabetic foot ulcer wounds remain unhealed after one year using current standards of care. Given these market dynamics, there is a clear need for a cost-effective and efficacious treatment option.

In February 2016, Reapplix's unique technology - a single use medical device used to prepare an autologous platelet-rich plasma (PRP) gel from the patient's peripheral blood by centrifugation, without the addition of any reagents - received US FDA 510(k) clearance to be put on market in the US as the 3C Patch System™, with the indication for use that under the supervision of a healthcare professional, the PRP gel produced by the 3C Patch System™ is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and mechanically or surgically-debrided wounds.

Reapplix ApS is a privately-held wound care company backed by three leading Danish investors, SEED Capital, Novo SEEDS and Vækstfonden (The Danish Growth Fund).

www.reapplix.com